Endo Health will spend about $1.5 billion to buy the Canadian specialty drug maker Paladin Labs, and both will then be folded into a newly formed Irish holding company. Endo also posted better-than-expected third-quarter results Tuesday and issued strong profit guidance for the year. Read the full story